Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma

Drug-induced pulmonary arterial hypertension (PAH) is constantly evolving as new drugs are developed. Carfilzomib is a recently approved therapy for relapsed and refractory multiple myeloma. While it has been associated with cardiovascular adverse events, such as ischemic heart disease and heart fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jenny Z., Buckstaff, Taylor, Narezkina, Anna, Fernandes, Timothy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485285/
https://www.ncbi.nlm.nih.gov/pubmed/34603687
http://dx.doi.org/10.1177/20458940211049300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485285/
https://www.ncbi.nlm.nih.gov/pubmed/34603687
http://dx.doi.org/10.1177/20458940211049300

Ejemplares similares